drugset / Trial / NCT07530367
A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis
Phase 3
Not yet recruiting
135 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease primarily affecting the palms and soles. Currently, no treatment is specifically approved for PPP globally. This study aims to evaluate the efficacy and safety of tofacitinib combined with imatinib in patients with moderate-to-severe PPP.
Timeline
- Start
- 2026-04-01
- Primary completion
- 2028-04-01
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 400 mg | — |
| Subject | Tofacitinib | Small molecule | 5 mg | Oral |